[go: up one dir, main page]

AU2001260109A1 - Mixture comprising an inhibitor or suppressor of a gene and molecule binding to an expression product of that gene - Google Patents

Mixture comprising an inhibitor or suppressor of a gene and molecule binding to an expression product of that gene

Info

Publication number
AU2001260109A1
AU2001260109A1 AU2001260109A AU6010901A AU2001260109A1 AU 2001260109 A1 AU2001260109 A1 AU 2001260109A1 AU 2001260109 A AU2001260109 A AU 2001260109A AU 6010901 A AU6010901 A AU 6010901A AU 2001260109 A1 AU2001260109 A1 AU 2001260109A1
Authority
AU
Australia
Prior art keywords
gene
suppressor
inhibitor
mixture
expression product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001260109A
Other languages
English (en)
Inventor
Karl-Hermann Schlingensiepen
Reimar Schlingensiepen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH
Original Assignee
Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH filed Critical Biognostik Gesellschaft fuer Biomolekulare Diagnostik mbH
Publication of AU2001260109A1 publication Critical patent/AU2001260109A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001260109A 2000-03-11 2001-03-10 Mixture comprising an inhibitor or suppressor of a gene and molecule binding to an expression product of that gene Abandoned AU2001260109A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00105190 2000-03-11
EP00105190A EP1133988A1 (fr) 2000-03-11 2000-03-11 Mélange comprenant un inhibiteur ou suppresseur d'un gène et une molécule se liant à un produit d'expression de ce gène
PCT/EP2001/002694 WO2001068146A2 (fr) 2000-03-11 2001-03-10 Melange comprenant un inhibiteur ou un suppresseur d'un gene et une molecule se liant au produit d'expression de ce gene

Publications (1)

Publication Number Publication Date
AU2001260109A1 true AU2001260109A1 (en) 2001-09-24

Family

ID=8168078

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001260109A Abandoned AU2001260109A1 (en) 2000-03-11 2001-03-10 Mixture comprising an inhibitor or suppressor of a gene and molecule binding to an expression product of that gene

Country Status (9)

Country Link
US (2) US20030186906A1 (fr)
EP (2) EP1133988A1 (fr)
JP (1) JP4843177B2 (fr)
AT (1) ATE304858T1 (fr)
AU (1) AU2001260109A1 (fr)
DE (1) DE60113511T2 (fr)
ES (1) ES2245364T3 (fr)
HK (1) HK1049796B (fr)
WO (1) WO2001068146A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242521A1 (en) * 1999-10-25 2004-12-02 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
US20060172925A1 (en) * 1998-10-26 2006-08-03 Board Of Regents, The University Of Texas System Thio-siRNA aptamers
US6867289B1 (en) * 1998-10-26 2005-03-15 Board Of Regents, The University Of Texas Systems Thio-modified aptamer synthetic methods and compositions
US20030162190A1 (en) * 2001-11-15 2003-08-28 Gorenstein David G. Phosphoromonothioate and phosphorodithioate oligonucleotide aptamer chip for functional proteomics
AU2003263853A1 (en) * 2002-08-16 2004-03-03 Board Of Regents The University Of Texas System Compositions and methods related to flavivirus envelope protein domain iii antigens
WO2005003291A2 (fr) * 2002-10-16 2005-01-13 Board Of Regents Of The University Of Texas System Banques combinatoires d'aptameres a groupes phosphorothioate et phosphorodithioate oligonucleotidiques lies a des billes
WO2005037053A2 (fr) * 2003-05-23 2005-04-28 Board Of Regents - The University Of Texas System Recherche systematique a haut debit, dans des echantillotheques d'aptameres, de liaisons specifiques avec des proteines sur des virus et d'autres pathogenes
WO2005032455A2 (fr) * 2003-05-23 2005-04-14 Board Of Regents Oligonucleoside phosphorothioate selectionnes de maniere combinatoire et a base structurelle et facteurs de transcription ap-1 ciblant un phosphorodithioate aptamere
US20050118611A1 (en) * 2003-07-24 2005-06-02 Board Of Regents, The University Of Texas System Thioaptamers enable discovery of physiological pathways and new therapeutic strategies
CA2550058C (fr) * 2003-12-19 2016-07-12 Antisense Pharma Gmbh Composition pharmaceutique comprenant un oligonucleotide antisens anti-tgf-beta2 et un agent chimiotherapeutique
EP2248895B8 (fr) 2003-12-19 2016-09-21 Autotelic LLC Thérapie combinatoire associant un antagoniste du TGF-beta avec un agent chimiothérapeutique
NZ548926A (en) * 2004-02-09 2009-07-31 Regenion Gmbh Inhibitors of TGF-R signaling for treatment of CNS disorders
CA2558667A1 (fr) * 2004-02-27 2005-09-15 Antisense Pharma Gmbh Oligonucleotides antisens visant a inhiber la formation de metastases dans le cancer
EP1568383A3 (fr) * 2004-02-27 2005-11-16 Antisense Pharma GmbH Utilisation d'un oligonucléotide ou d'un dérivé actif pour la préparation d'une composition pharmaceutique inhibant la formation de métastases dans le traitement du cancer
US20050239134A1 (en) * 2004-04-21 2005-10-27 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
AU2006243218B2 (en) 2005-05-05 2009-09-17 Antisense Pharma Gmbh Use of low doses of oligonucleotides antisense to TGF-beta, VEGF, interleukin-10, c-jun, c-fos or prostaglandin E2 genes in the treatment of tumors
WO2008009437A2 (fr) 2006-07-18 2008-01-24 Noxxon Pharma Ag Acides nucléiques de liaison à sdf-i
KR101589442B1 (ko) * 2007-08-06 2016-02-01 녹손 파르마 아게 에스디에프-1 결합형 핵산 및 이의 용도
DE102007056488A1 (de) * 2007-11-22 2009-07-23 Biontex Laboratories Gmbh Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
EP2580326A1 (fr) 2010-06-11 2013-04-17 Antisense Pharma GmbH Procédé pour une modification sélective d'oligonucléotides
US9427458B2 (en) 2010-07-22 2016-08-30 Consejo Nacional De Investigaciones Cientificas Y Tecnicas, Conicet Methods for inhibiting cancer cell proliferation
CN104800858B (zh) * 2015-04-27 2017-11-21 中国医学科学院基础医学研究所 Hsp90抑制肽偶联物及其在肿瘤治疗中的应用
WO2017138924A1 (fr) 2016-02-09 2017-08-17 Autotelic Llc Compositions et méthodes de traitement du cancer du pancréas
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
WO2024254199A1 (fr) * 2023-06-05 2024-12-12 Gmp Biotechnology Limited Agents tgfb2 anticancéreux à agents immunothérapeutiques

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5733523A (en) * 1990-12-10 1998-03-31 Akzo Nobel N.V. Targeted delivery of a therapeutic entity using complementary oligonucleotides
IL108367A0 (en) * 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
ATE211762T1 (de) 1993-04-30 2002-01-15 Biognostik Ges Antisense-oligonukleotide zur behandlung des immunsuppressiven effektes des transformierenden wachstumsfaktor-beta1(tgf-beta1)
US5683902A (en) * 1994-05-13 1997-11-04 Northern Illinois University Human papilloma virus inhibition by a hairpin ribozyme
US5958769A (en) * 1996-01-18 1999-09-28 Fred Hutchinson Cancer Research Center Compositions and methods for mediating cell cycle progression
US20020165174A1 (en) * 1997-01-31 2002-11-07 Gill Parkash S. Methods and compositions for antisense VEGF oligonucleotides
US6248723B1 (en) * 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
EP0945507A1 (fr) * 1998-03-27 1999-09-29 Boehringer Mannheim Gmbh Region de régulation d'expression spécifique de tumeur et son utilisation
AU5087799A (en) * 1998-07-06 2000-01-24 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
US6900299B1 (en) * 1999-03-11 2005-05-31 University Of South Florida Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection

Also Published As

Publication number Publication date
WO2001068146A2 (fr) 2001-09-20
DE60113511T2 (de) 2006-06-22
EP1263446B1 (fr) 2005-09-21
JP4843177B2 (ja) 2011-12-21
US8703729B2 (en) 2014-04-22
ES2245364T3 (es) 2006-01-01
WO2001068146A3 (fr) 2002-01-31
JP2003526684A (ja) 2003-09-09
HK1049796A1 (en) 2003-05-30
EP1263446A2 (fr) 2002-12-11
EP1133988A1 (fr) 2001-09-19
DE60113511D1 (de) 2006-02-02
ATE304858T1 (de) 2005-10-15
HK1049796B (en) 2006-01-20
US20090285817A1 (en) 2009-11-19
US20030186906A1 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
AU2001260109A1 (en) Mixture comprising an inhibitor or suppressor of a gene and molecule binding to an expression product of that gene
AU2001239725A1 (en) Antibacterial agents
AU2001266896A1 (en) Improved injectable dispersions of propofol
AU2001273063A1 (en) Stabilized interleukin 2
AU2001283307A1 (en) Hydrocarbon gas processing
GB2382110A (en) Clutch assembly
AU2001292760A1 (en) Internet insurance product
AU2001296961A1 (en) 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
AU2002221884A1 (en) Delta 1-pyrrolines used as pesticides
AU2002225894A1 (en) Methods and compositions for the control of coccidiosis
AU6279500A (en) Epothilone compositions
AU2001250428A1 (en) Genes of the 1-desoxy-d-xylulose biosynthesis path
AU2001247166A1 (en) Process for the desulfurization of petroleum feeds
AU2000278051A1 (en) Stabilized emulsion compositions
AU1800200A (en) Character input keyboard
AU2002224153A1 (en) Skid board
AU3315200A (en) 1,5-anhydro-d-fructose substituted with a hydrophobic group for use as anti-oxidant and/or emulsifier
MY140504A (en) Statin-mmp inhibitor combinations
AU2001268689A1 (en) Alpha-arylated cinnamic esters and 1,4-bis(alpha-carboxyl-beta-styryl)benzene esters as uv-blocking agents
EP1351680B8 (fr) Utilisation de l'anethole-dithiolethione dans la prevention et le traitement de la tenotoxicite induite par un medicament
AU2002243394A1 (en) Aryloxy piperidinyl derivatives for the treatment of depression
AUPQ746000A0 (en) X-band 2000
AU2001259228A1 (en) Pancreatic progenitor 1 gene and its uses
AU2001291845A1 (en) Delta1-pyrrolines used as pesticides
AU2002221623A1 (en) Gene 4